Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Abortion with sulprostone, a prostaglandin E2 derivative.

M O Pulkkinen, P Kajanoja, A Kivikoski

    International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics
    |July 1, 1980
    PubMed
    Summary

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Well-being of persons preparing extensive health and social services reform.

    Occupational medicine (Oxford, England)·2025
    Same author

    Subconjunctival haemorrhage in 147 dogs.

    The Journal of small animal practice·2019
    Same author

    [Fetal breech presentation--an elective cesarean section or vaginal delivery?].

    Duodecim; laaketieteellinen aikakauskirja·2002
    Same author

    Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2002
    Same author

    Alendronate disturbs vesicular trafficking in osteoclasts.

    Calcified tissue international·2002
    Same author

    A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2001

    Sulprostone, a prostaglandin E2 derivative, effectively terminated pregnancies up to 21 weeks. This medication was well-tolerated across various administration routes, offering a safe and practical option for medical abortion.

    Area of Science:

    • Obstetrics and Gynecology
    • Reproductive Medicine
    • Pharmacology

    Background:

    • Prostaglandins are widely used for pregnancy termination.
    • Sulprostone, a prostaglandin E2 derivative, offers potential advantages in efficacy and tolerability.

    Purpose of the Study:

    • To evaluate the efficacy and safety of sulprostone for terminating pregnancies between 8-21 weeks' gestation.
    • To compare different routes of administration for sulprostone.

    Main Methods:

    • A multicenter clinical trial involving 478 participants.
    • Administration of sulprostone via extraovular, intravenous, and intramuscular routes.
    • Assessment of abortion rates and side effects at 24 hours post-treatment.

    Main Results:

    Keywords:
    Abortifacient AgentsAbortion, InducedBiologyClinical ResearchEndocrine SystemFamily PlanningFertility Control, PostconceptionPhysiologyPregnancyPregnancy, First TrimesterPregnancy, Second TrimesterProstaglandins--administraction and dosageProstaglandins--side effectsReproductionResearch Methodology

    Related Experiment Videos

    • High abortion rates (67%-88%) were achieved within 24 hours.
    • Sulprostone was well-accepted by patients without premedication.
    • Intravenous infusion demonstrated the highest safety profile, while intramuscular injection was most practical.

    Conclusions:

    • Sulprostone is an effective and well-tolerated agent for pregnancy termination in the second trimester.
    • Intravenous administration is recommended for safety, with intramuscular injection offering practical advantages.
    • Sulprostone presents a favorable clinical profile compared to primary prostaglandins.